Brief: Ryvu Therapeutics Withdraws From Grant Agreement To Identify PRMT5 Inhibitor Markers
08/04/2025 16:05
April 8 (Reuters) - Ryvu Therapeutics SA RVU.WA: WITHDRAWS FROM GRANT AGREEMENT WITH MEDICAL RESEARCH AGENCY FOR IDENTIFICATION OF MARKERS TO SELECT PATIENTS FOR PRMT5 INHIBITOR THERAPY DECISION DUE TO CHANGE IN RESEARCH SCOPE TOWARDS BRAIN TUMORS Source text: ID:nEMFFrlJa Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Q1 Net Loss 12.6 Million Zlotys
Brief: Ryvu Therapeutics Updates Romacyclib Development Strategy
Brief: Ryvu Therapeutics FY Net Loss At 101.2 Mln Zlotys
Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
Brief: Ryvu Therapeutics Signs Grant Agreement With Poland's NCBR For PERO Project